Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Year: 2018
Type: article
Abstract: Measurable residual disease (MRD; previously termed minimal residual disease) is an independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is important for risk stratification and treatment planning, in conjunction with other well-established clinical, cytogenetic, and molecular data assessed at diagnosis. MRD can be evaluated using a variety of multiparameter flow cytometry and molecular protocols, but, to date, these approaches have not been qualitatively or quantitatively standardized, making their use in clinical practice challenging. The objective of this work was to identify key clinical and scientific issues in the measurement and application of MRD in AML, to achieve consensus on these issues, and to provide guidelines for the current and future use of MRD in clinical practice. The work was accomplished over 2 years, during 4 meetings by a specially designated MRD Working Party of the European LeukemiaNet. The group included 24 faculty with expertise in AML hematopathology, molecular diagnostics, clinical trials, and clinical medicine, from 19 institutions in Europe and the United States.
Source: Blood
Authors: Gerrit J. Schuurhuis, Michael Heuser, Sylvie Freeman, Marie-Christine Béné, Francesco Buccisano, Jacqueline Cloos, David Grimwade, Torsten Haferlach, Robert K. Hills, Christopher S. Hourigan, Jeffrey L. Jorgensen, Wolfgang Kern, Francis Lacombe, Luca Maurillo, Claude Preudhomme, Bert A. van der Reijden, Christian Thiede, Adriano Venditti, Paresh Vyas, Brent L. Wood, Roland B. Walter, Konstanze Döhner, Gail J. Roboz, Gert J. Ossenkoppele
Institutions: Amsterdam UMC Location Vrije Universiteit Amsterdam, Medizinische Hochschule Hannover, University of Birmingham, Centre Hospitalier Universitaire de Nantes, Nantes Université, University of Rome Tor Vergata, King's College London, Munich Leukemia Laboratory (Germany), Cardiff University, National Institutes of Health, The University of Texas MD Anderson Cancer Center, Centre Hospitalier Universitaire de Bordeaux, Université de Lille, Centre Hospitalier Universitaire de Lille, Radboud University Nijmegen, Radboud University Medical Center, University Hospital Carl Gustav Carus, Technische Universität Dresden, National Health Service, University of Oxford, Oxford University Hospitals NHS Trust, Medical Research Council, Fred Hutch Cancer Center, University of Washington, Universität Ulm, University Hospital Ulm, NewYork–Presbyterian Hospital, Weill Cornell Medicine
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Awards: G1275602140, G1859382319, NIHR Senior Investigator Award, G49620643, G5095217403, G6095898982, Clinical Investigation of a Humanized Anti-CD47 Antibody in Targeting Cancer Stem Cells in Acute Myelodi Leukaemia (and Solid Tumours)., G6412636814, G6644305583, G7201224627, G7996824345, G8507756562, G9000342419
OpenAlex ID: W2783450169